Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancies (R/R BCM). Attempting to make CAR T-cells safer and more effective in treating R/R BCM, various novel engineered CAR T-cell agents are currently in the research and development or clinical trial stages. We have summarized here the latest reports on the novel CAR T-cell therapies for R/R BCM presented at the 2023 ASH Annual Meeting as well as the latest updates in related clinical trials.

中文翻译：

---

用于治疗复发/难治性 B 细胞恶性肿瘤的新型 CAR T 细胞疗法：2023 年 ASH 年会的最新更新

嵌合抗原受体 (CAR) 是一种工程融合蛋白，可将 T 细胞靶向肿瘤细胞的特定表面抗原，从而产生有效的抗肿瘤反应。 CAR T 细胞疗法在复发/难治性 B 细胞恶性肿瘤 (R/R BCM) 的治疗中发挥着越来越重要的作用。为了使 CAR T 细胞更安全、更有效地治疗 R/R BCM，各种新型工程 CAR T 细胞制剂目前正处于研发或临床试验阶段。我们在此总结了2023年ASH年会上发布的针对R/R BCM的新型CAR T细胞疗法的最新报告以及相关临床试验的最新进展。